Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up - Time to Buy?

Key Points

• Ascentage Pharma shares rose 7.1%, opening at $18.49 versus a prior close of $16.85, before trading near $18.32.
• Analysts remain bullish, with a consensus “Buy” rating and an average price target of $46.43; recent targets range from $40 to $48.
• Institutional interest has increased, including UBS Group’s 149.4% expansion of its holdings, while the clinical-stage biotech continues developing cancer therapies targeting cell-death pathways.

Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report) gapped up prior to trading on Friday . The stock had previously closed at $16.85, but opened at $18.49. Ascentage Pharma Group International shares last traded at $18.3240, with a volume of 501 shares.

Analysts Set New Price Targets

A number of research analysts have issued reports on AAPG shares. Raymond James Financial restated a "buy" rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. Deutsche Bank Aktiengesellschaft initiated coverage on Ascentage Pharma Group International in a research report on Friday, April 24th. They issued a "buy" rating and a $40.00 target price on the stock. B. Riley Financial assumed coverage on Ascentage Pharma Group International in a research note on Wednesday, June 10th. They issued a "buy" rating and a $45.00 target price for the company. Finally, BTIG Research reiterated a "buy" rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a research note on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $46.43.

Ascentage Pharma Group International Stock Up 7.1%

The stock has a 50 day simple moving average of $18.11 and a two-hundred day simple moving average of $21.74. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.77 and a current ratio of 1.79.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of AAPG. Citadel Advisors LLC acquired a new position in Ascentage Pharma Group International in the third quarter valued at approximately $383,000. UBS Group AG increased its holdings in shares of Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company's stock valued at $716,000 after purchasing an additional 10,988 shares in the last quarter. Finally, Hsbc Holdings PLC purchased a new position in shares of Ascentage Pharma Group International during the 2nd quarter valued at approximately $391,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source